The FY2025 (Dec) proxy of C4 Therapeutics names 20 peer companies for pay. Among C4 Therapeutics and these peers, CEO pay was 10th highest of 14 and total shareholder return was 8th highest of 13.
10th highest of 14in C4 Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$1.5M$8.5M
8th highest of 13in C4 Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$6$15,536
Pay peer group, FY2025 (Dec) proxy
| Kymera Therapeutics | ||
| Arvinas | ||
| Nurix Therapeutics | ||
| Oric Pharmaceuticals | ||
| Cullinan Therapeutics | ||
| Relay Therapeutics | ||
| Lyell Immunopharma | ||
| Fulcrum Therapeutics | ||
| Nkarta | ||
| Tango Therapeutics | Not disclosed | |
| Editas Medicine | ||
| Black Diamond Therapeutics | ||
| Adicet Bio | ||
| Foghorn Therapeutics | Not disclosed | Not disclosed |
| IGM Biosciences, Inc. | Not disclosed | Not disclosed |
| Monte Rosa Therapeutics | Not disclosed | Not disclosed |
| Poseida Therapeutics, Inc. | Not disclosed | Not disclosed |
| Prelude Therapeutics Incorporated | Not disclosed | Not disclosed |
| Sutro Biopharma | Not disclosed | Not disclosed |
| iTeos Therapeutics, Inc. | Not disclosed | Not disclosed |
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
20 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.